Glecaprevir + Pibrentasvir

Category: Hepatitis

Glecaprevir + Pibrentasvir Overview

Glecaprevir/pibrentasvir (trade name Mavyret in the US and Maviret in Europe) is a combination drug containing glecaprevir (100mg) and pibrentasvir (40mg). In the United States, it was approved by the Food and Drug Administration in August 2017 for treatment of hepatitis C.[1] In Europe, it was also approved in August 2017 for the same indication.[2] Contents 1 Medical uses 2 Side effects 3 Clinical trials 4 Development 5 References Medical uses Mavyr...

Read more Glecaprevir + Pibrentasvir Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Glecaprevir/pibrentasvir

Recent Glecaprevir + Pibrentasvir Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Glecaprevir + Pibrentasvir

Tablet: 100mg + 40mg

Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Drugs with one or more similar ingredients: (1 result)

MAVYRET Glecaprevir + Pibrentasvir2 discussions